Reasons for consideration, page-96

I don't think that a discussion of off-label drug use has done the rounds recently. Going back to a couple of my old posts from January 2015 for easy-to-find-research;

'According to one source, more than one in five outpatient prescriptions written in the US are for off-label therapies. The FDA regulates drug approval but doctors prescribe drug use,' and

'Off-label drug use (OLDU) may even be considered integral to public health. OLDU occurs in virtually every therapeutic area and is relatively common in pediatrics as well as elderly populations. Once approved, it is generally accepted that physicians may prescribe drugs for any therapeutic use which is considered appropriate in their medical judgement. The use of OLDU may highlight conditions which warrant supplementary clinical trials'.

Once Trofinetide is approved for Retts, particularly given its safety profile, could it be prescribed for instance in elderly populations for conditions such as dementia and Alzheimer disease?